

## Transaction Contacts

Coverage Team: Murphy Gallagher  
Joe Winningham

ECM Team: Rahul Chaudhary



**\$100 Million**  
Follow-On Offering

**LEERINK   
PARTNERS**  
Joint Bookrunner  
September 2023

## Leerink Partners Serves as Joint Bookrunner for HilleVax's (Nasdaq: HLVX) \$100 Million Follow-On Offering

### Key Transaction Highlights

- Confidentially marketed deal that publicly launched on September 19th post-close and priced overnight.
- Well oversubscribed from both new and existing investors.
- Base deal consisted of 8,000,000 shares at a price of \$12.50 per share, representing a 13.4% discount to launch.
- HilleVax intends to use the net proceeds from this offering, together with its existing cash and cash equivalents, to fund the clinical development of HIL-214, including certain manufacturing activities, and for working capital and general corporate purposes.
- This is Leerink Partners' 2nd bookrun equity offering for HilleVax and 41st equity offering in 2023.

If you would like to unsubscribe from this distribution, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF LEERINK PARTNERS LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THESE SECURITIES HAVE BEEN SOLD. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

BOSTON  
53 State Street  
40th Floor  
Boston, MA 02109

CHARLOTTE  
2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

NASHVILLE  
40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

NEW YORK  
1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

SAN FRANCISCO  
255 California Street  
12th Floor  
San Francisco, CA 94111

[LEERINK.COM](https://www.leerink.com)